Meningococcal serogroup C conjugate vaccine.
Meningococcal meningitis and septicaemia are important causes of morbidity and mortality in many parts of the world. More than 90% of the cases are caused by serogroups A, B and C; the remaining 10% are largely caused by the W-135 and Y strains. During the mid-to-late 1990s there was an increase in meningococcal serogroup (MS) C disease in the UK and some parts of Europe. MS C polysaccharide vaccines that were developed in the 1960s are weakly immunogenic and not protective in infants under 2 years of age, but are effective in older recipients. Meningitec (Wyeth-Ayerst) is produced by conjugation of serogroup C oligosaccharide with a mutant diphtheria protein (CRM197), with the aim of inducing T-cell dependent immune responses. It has been found to be immunogenic in infants, toddlers, older children and adults. The vaccine has also been shown to induce immunological memory and therefore is likely to give long-term protection against disease. It received a license for use in the UK in October 1999 and was introduced into the UK immunisation schedule in November 1999. Surveillance studies after introduction of this and similar vaccines have demonstrated a dramatic fall in the incidence of MS C disease. Pre-licensure research studies and post-licensure adverse event data have confirmed that the vaccine is safe.
Lakshman
Raman
R
Institute of Child Health, UBHT Education Centre, c/o Paul O'Gorman Building, Royal Hospital for Children, University of Bristol, Bristol, BS2 8BJ UK.
Finn
Adam
A
D000328:Adult; D000818:Animals; D001428:Bacterial Vaccines / Q000627:therapeutic use*; D002648:Child; D006801:Humans; D000922:Immunotoxins / Q000009:adverse effects / Q000276:immunology*; D008585:Meningitis, Meningococcal / Q000276:immunology*; D009345:Neisseria meningitidis / Q000276:immunology*; D011134:Polysaccharides / Q000276:immunology
D001428:Bacterial Vaccines; D000922:Immunotoxins; D011134:Polysaccharides